drugset / Trial / NCT02259686

Cardiovascular Effects of Apelin In Healthy Volunteers

NCT02259686

Phase 0 Completed 14 enrolled University of Edinburgh NHS Lothian · collab
RandomizedCrossoverOpen-label

Summary

Apelin is an endogenous peptide with physiological actions in the cardiovascular system. Apelin can modulate vasomotor tone and is a potent endogenous inotrope. In a series of clinical studies, we have shown that apelin causes peripheral and coronary vasodilatation and increased cardiac contractility. We wish to study and compare the cardiovascular effects of subcutaneous versus intravenous apelin. We specifically wish to determine how different methods of apelin administration affect cardiac output and peripheral vascular resistance in healthy volunteers

Timeline

Start
2014-11
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Apelin Peptide 1 mg Subcutaneous
Subject Apelin Peptide 5 mg Subcutaneous
Subject Apelin Peptide 10 mg Subcutaneous

Indications

No indication recorded.